Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Venom immunotherapy (VIT) and adrenaline autoinjector (AAI) are important therapies in venom anaphylaxis. Adherence to VIT and AAI in patients with venom allergy has been evaluated in a few studies; however, solid data are lacking. This study aimed to evaluate VIT and AAI retrieval rates in patients with venom allergy with a special focus on adherence to treatment. Adherence was compared to subcutaneous immunotherapy (SCIT) with inhalant allergens.
Methods: This was a retrospective study among patients registered for allergen immunotherapy at the Allergy Center, Odense University Hospital, Denmark, from January 1, 2010, to December 31, 2014. Data on purchased immunotherapy and AAI were obtained from the Danish National Health Service Prescription Database. Multivariable logistic regression was used to analyze if allergen, age, sex, mastocytosis, and treatment site affected adherence.
Results: The 3-year adherence to VIT was 92.4% (244/264) compared to 87.4% (215/246) in SCIT with inhalant allergens, and the 5-year adherence to VIT was 84.1% (222/264) compared to 74.8% (184/246) in SCIT with inhalant allergens (p = 0.045). Females treated with VIT were more adherent than males (p = 0.45 [3-year], p = 0.008 [5-year]), whereas allergen, age, mastocytosis, or treatment site did not significantly affect adherence. Only 28.6% of patients (12/42) purchased an AAI after premature termination of VIT.
Conclusion: In this register-based study, we found that the 3- and 5-year adherences to VIT and SCIT with inhalant allergens are at the upper end of the spectrum hitherto reported. Patients' 5-year adherence to VIT was higher than patients' 5-year adherence to SCIT with inhalant allergens. If VIT was prematurely terminated, less than 1/3 would have purchased an AAI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000535294 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of the characteristics of blood inflammatory cytokines and their influencing factors in acute exacerbations of allergic asthma in children.
Front Pediatr
April 2025
Department of Laboratory Medicine, Yuhuan People's Hospital, Taizhou, China.
Background: Exploring the characteristics of serum inflammatory cytokine changes during acute exacerbations of pediatric allergic asthma, and analyzing factors influencing poor asthma control and predictive indicators.
Methods: Forty children with acute exacerbations of allergic asthma, either outpatients or inpatients, were selected as the observation group, and 40 healthy children undergoing physical examinations during the same period served as the control group. Flow cytometry was used to analyze the characteristics of blood inflammatory cytokines in both groups.
Effect and mechanism of allergen-specific immunotherapy on small airway dysfunction in children with asthma.
Pediatr Pulmonol
January 2025
Department of Respiratory Medicine, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Background: The purpose of this study was to investigate the effectiveness of allergen-specific immunotherapy (AIT) on small airway dysfunction (SAD) and the underlying mechanism with a special focus on basophils.
Methods: Sixty-five children with mild to moderate asthma who were under regular inhaled corticosteroid (ICS) treatment for more than 1 year but whose FEF remained below 65% of the predicted value and had positive results for serum Der p or Der f were enrolled. Children with asthma underwent house dust mite (HDM) subcutaneous immunotherapy (SCIT) treatment for 1 year.
Eosinophilic esophagitis and inhalant antigens: Pointing out the roles of allergic rhinitis, immunotherapy and biologic treatment.
World Allergy Organ J
October 2024
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Article Synopsis
- - Eosinophilic esophagitis (EoE) and allergic rhinitis (AR) are linked through a common type 2 inflammation response, with AR frequently occurring in EoE patients and both being influenced by aeroantigens and seasonal factors.
- - Current research struggles to establish clear conclusions regarding the relationship between EoE and AR due to study designs that may not adequately account for various external factors, making pollen counts a potentially more reliable indicator of EoE exacerbations.
- - Allergen immunotherapy's effects on EoE symptoms are still uncertain, with sublingual immunotherapy typically causing exacerbations while subcutaneous immunotherapy may aid in remission; monoclonal antibodies may offer future treatment possibilities
[Efficacy and safety of dust mite subcutaneous immunotherapy in children with allergic asthma： a prospective randomized controlled study].
Zhongguo Dang Dai Er Ke Za Zhi
June 2024
Department of Pediatrics, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, China.
Article Synopsis
- Researchers wanted to see if a treatment with dust mites called SCIT helps kids with allergic asthma and is safe to use.
- They studied 98 children, splitting them into two groups, where one group got regular asthma medicine and the other group got both the regular medicine and SCIT for three years.
- Results showed that kids who received SCIT had better asthma control and fewer symptoms over three years, and the treatment was mostly safe, with very few side effects.
Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma.
J Allergy Clin Immunol Pract
June 2024
Allergy & Clinical Immunology, Division of Respiratory Science, National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, United Kingdom.
Allergen immunotherapy (AIT) is a recognized key therapeutic modality for the treatment of allergic respiratory disease. Definitive studies have provided evidence-based data to demonstrate its effectiveness in allergic rhinitis and asthma due to the inhalation of proteinaceous allergic substances from specific seasonal pollens, dust mites, animal allergens, and certain mold spores. Over the ensuing decades, laboratory investigations have provided objective evidence to demonstrate immunologic changes, including production of protective IgG antibody, suppression of IgE antibody, upregulation of regulatory T cells, and induction of a state of immune tolerance to the offending allergen(s).
View Article and Find Full Text PDF